23 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Digestive Diseases Audio PeerVoice

    • Science

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Proactive IBD Care: Identifying Patients at Risk of Disease Progression

    Proactive IBD Care: Identifying Patients at Risk of Disease Progression

    Visit https://www.peervoice.com/QGY860 to view the entire programme with slides. After completing “Proactive IBD Care: Identifying Patients at Risk of Disease Progression”, participants will be able to: Explain the rationale for assessing risk of progression and individualising therapy for patients with inflammatory bowel disease (IBD); Apply emerging risk assessment strategies to identify patients with IBD at risk of progression; and Design effective treatment plans for patients with IBD according to risk stratification.

    • 23 min
    Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management

    Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management

    Visit https://www.peervoice.com/GWP860 to view the entire programme with slides. After completing “Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management ”, participants will be able to: Discuss the most recent and relevant clinical data that most impacts the systemic treatment of patients with unresectable hepatocellular carcinoma (HCC); Formulate personalised, evidence-based sequencing strategies, developed through a multidisciplinary approach, that optimise the survival of patients with unresectable HCC; and Apply a balanced approach to maximise patient quality of life over the duration of the treatment plan.

    • 16 min
    New Targets in IBD: Focus on IL-23

    New Targets in IBD: Focus on IL-23

    Visit https://www.peervoice.com/HHK860 to view the entire programme with slides. After completing “New Targets in IBD: Focus on IL-23”, participants will be able to: Explain the rationale for targeting IL-23 in inflammatory bowel disease (IBD); Evaluate the relative efficacy and safety of IL-23 inhibitors to date for patients with IBD; and Describe how these agents may fit into future treatment algorithms for IBD.

    • 18 min
    Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease

    Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease

    Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease

    • 21 min
    Transforming the Treatment of Acute Hepatic Porphyria

    Transforming the Treatment of Acute Hepatic Porphyria

    Transforming the Treatment of Acute Hepatic Porphyria

    • 17 min
    Early Disease Control in Inflammatory Bowel Disease: Integrating the Latest Evidence for Better Outcomes

    Early Disease Control in Inflammatory Bowel Disease: Integrating the Latest Evidence for Better Outcomes

    Early Disease Control in Inflammatory Bowel Disease: Integrating the Latest Evidence for Better Outcomes

    • 18 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerVoice